Pharmabiz1h
EMA committee recommends approval of Eisai & Biogen’s lecanemab to treat early Alzheimer’s disease
EMA committee recommends approval of Eisai & Biogen’s lecanemab to treat early Alzheimer’s disease: Tokyo Saturday, November 16, 2024, 13:00 Hrs [IST] Eisai Co., Ltd. and Biog ...
latestnewsandupdates8h
Alzheimer’s, how much socioeconomic factors weigh on the risk of getting sick
Blurring memory. Affects that cancel each other out. The mind that appears distant, almost unattainable. As if an ...
Neuroscience News19h
Brain Circuits for Spatial Memory and Navigation Identified
Researchers have identified two neural circuits in the retrosplenial cortex (RSC) that are critical for spatial navigation ...
Psychology Today12h
Your Body and Brain in Motion Are Where Mind and Matter Meet
Everything is connected. Our efforts to move and improve generate multiple cascading responses within our bodies that can ...
PharmiWeb22h
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease
Eisai Europe Ltd. and Biogen Inc. announced today that a positive opinion has been received from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) ...